USE OF ANTIPNEUMOCOCCIC REFINED SERUM IN LOBAR PNEUMONIA

Publisher Website
Google Scholar
Abstract
Practicing physicians have not as yet adopted the serum treatment for pneumonia. This has mainly been because the available serums have required relatively large intravenous injections, have been monovalent, and at times have occasioned severe reactions. Moreover, the beneficial effects have not been conclusively proved. In fact, the typing of pneumococci obtained from patients suffering from pneumonia has been abandoned in many hospitals, because it has been regarded as a procedure of little or no clinical value. But the results of treatment of type I patients by Avery and Cole and their co-workers, the recent studies of serums in experimental pneumonia in monkeys by Cecil, and the protection experiments on mice, all influenced Dr. Park to continue his efforts. We have used Felton's serum, refined in the cold, and made available through the Influenza Commission of the Metropolitan Life Insurance Company and Harvard University, and preparations of Dr. Banzhaf and

This publication has 0 references indexed in Scilit: